GS-441524
GS-441524 is a nucleoside analogue antiviral drug which was developed by Gilead Sciences. It is the main plasma metabolite of the antiviral prodrug remdesivir, and has a half-life of around 24 hours in human patients. Remdesivir and GS-441524 were both tested against feline infectious peritonitis (FIP) in cell culture and found to be equivalent. Remdesivir was never tested in cats (though some vets now offer it) but GS-441524 has been found to be effective treatment for FIP, a lethal coronavirus disease which affects domestic cats and is widely used despite no official FDA approval due to Gilead's refusal to license this drug for veterinary use.
Q846227
antiviral
Concept
Q663596
Gilead Sciences
ORG
Q79749
plasma
Concept
Q603741
prodrug
Concept
Q28209496
remdesivir
MEDIA
Q28209496
Remdesivir
MEDIA
Q9692
feline infectious peritonitis
Concept
Q89469904
coronavirus
Concept
Q204711
FDA
Concept
Q94518604
GS-441524
DIS
Q94518604
GS-441524
DIS
Q94518604
GS-441524
DIS
-441524^^http://www.w3.org/2001/XMLSchema#decimal
-441524
NUMBER
+24^^http://www.w3.org/2001/XMLSchema#decimal
24
NUMBER
-441524^^http://www.w3.org/2001/XMLSchema#decimal
-441524
NUMBER
-441524^^http://www.w3.org/2001/XMLSchema#decimal
-441524
NUMBER
instance of
instance of